Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1998-4-30
pubmed:abstractText
Unmethylated CpG dinucleotides in bacterial DNA or synthetic oligodeoxynucleotides (ODN) cause B cell proliferation and Ig secretion, monocyte cytokine secretion, and activation of NK cell lytic activity and IFN-gamma secretion in vivo and in vitro. The potent immune activation by CpG ODN suggests possible utility for enhancing immune responses to vaccines. Mice immunized with recombinant hepatitis B virus surface Ag and a CpG ODN as an immune enhancer have titers of Abs against HBsAg (anti-HBs) that are five times higher than those of mice immunized with HBsAg and the standard adjuvant, aluminum hydroxide (alum). Ab titers in mice immunized with HBsAg and both CpG ODN plus alum were 35 times higher than the titers in mice immunized with alum alone, indicating a strong synergistic interaction between the CpG ODN and alum. ODN without CpG motifs had little or no immune-enhancing activity at the doses used herein. Alum induces a Th2 humoral response (mostly IgG1) and no CTL. In contrast, CpG ODN gives a strong Thl response with predominantly IgG2a Abs and CTL, even when mixed with alum. In vitro studies to determine possible mechanisms of CpG immune-enhancing effects show that CpG ODN induce expression of costimulatory molecules on Ag-presenting cells and drive B cell isotype switching in the appropriate cytokine milieu. These studies demonstrate that CpG ODN are promising new immune enhancers for vaccination applications.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
160
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
870-6
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:9551923-Adjuvants, Immunologic, pubmed-meshheading:9551923-Alum Compounds, pubmed-meshheading:9551923-Animals, pubmed-meshheading:9551923-B-Lymphocytes, pubmed-meshheading:9551923-Cells, Cultured, pubmed-meshheading:9551923-CpG Islands, pubmed-meshheading:9551923-Cytotoxicity, Immunologic, pubmed-meshheading:9551923-Female, pubmed-meshheading:9551923-Hepatitis B Surface Antigens, pubmed-meshheading:9551923-Immunoglobulin Class Switching, pubmed-meshheading:9551923-Immunoglobulin G, pubmed-meshheading:9551923-Lymphocyte Activation, pubmed-meshheading:9551923-Mice, pubmed-meshheading:9551923-Mice, Inbred BALB C, pubmed-meshheading:9551923-Oligodeoxyribonucleotides, pubmed-meshheading:9551923-Recombinant Proteins, pubmed-meshheading:9551923-Th1 Cells, pubmed-meshheading:9551923-Vaccines, DNA
pubmed:year
1998
pubmed:articleTitle
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
pubmed:affiliation
Loeb Research Institute, Ottawa Civic Hospital, ON, Canada. hdavis@civich.ottawa.on.ca
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't